These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9849465)

  • 1. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques.
    Monnet I; Brienza S; Hugret F; Voisin S; Gastiaburu J; Saltiel JC; Soulié P; Armand JP; Cvitkovic E; de Cremoux H
    Eur J Cancer; 1998 Jun; 34(7):1124-7. PubMed ID: 9849465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
    Riggi M; Ruffie P; Voisin S; Monnet I; de Cremoux H; Saltiel JC; Martin M; Vergne L; Huet J; Cvitkovic E
    Eur J Cancer; 1991; 27(10):1238-42. PubMed ID: 1659842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques).
    Riggi M; Cvitkovic E; de Cremoux H; Ruffie P; Monnet I; Voisin S; Villalobos W; Azli N; Saltiel JC
    Eur J Cancer; 1993; 29A(13):1914-5. PubMed ID: 8260254
    [No Abstract]   [Full Text] [Related]  

  • 5. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
    Raez LE; Kobina S; Santos ES
    Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
    Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
    Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer.
    Monnet I; Soulié P; de Cremoux H; Saltiel-Voisin S; Bekradda M; Saltiel JC; Brain E; Dupont-André G; Cvitkovic E
    J Clin Oncol; 2001 Jan; 19(2):458-63. PubMed ID: 11208839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
    Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.
    Zhang K; Qin H; Pan F; Liu E; Liang H; Ruan Z
    Med Sci Monit; 2014 Dec; 20():2830-6. PubMed ID: 25548985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
    Belvedere O; Follador A; Rossetto C; Merlo V; Defferrari C; Sibau AM; Aita M; Dal Bello MG; Meduri S; Gaiardo M; Fasola G; Grossi F
    Eur J Cancer; 2011 Jul; 47(11):1653-9. PubMed ID: 21514147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
    Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
    Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Lopes G; Rosado MF; Negret LM; Rocha-Lima C; Tolba K; Farfan N; Hamilton-Nelson K; Silva O; Roman E
    Lung Cancer; 2006 Sep; 53(3):347-53. PubMed ID: 16844257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
    Kakolyris S; Ziras N; Vamvakas L; Varthalitis J; Papakotoulas P; Syrigos K; Vardakis N; Kalykaki A; Amarantidis K; Georgoulias V
    Lung Cancer; 2006 Dec; 54(3):347-52. PubMed ID: 17030075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
    Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of carboplatin in non-small cell lung cancer.
    Tamura T; Shinkai T; Eguchi K; Sasaki Y; Fujiwara Y; Fukuda M; Ohe Y; Nakagawa K; Minato K; Saijo N
    Jpn J Clin Oncol; 1989 Mar; 19(1):51-5. PubMed ID: 2537907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
    Kataja V; Yap A
    Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.